Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07642414 · ClinicalTrials.gov registry record · NA
A Comprehensive Digital Care Program for Migraine Management
A NA study, sponsored by Hinge Health.
- Recruiting
- Registry status
- NA
- Development phase
- 140
- Enrollment target
NCT07642414: Recruiting NA study, sponsored by Hinge Health.
NCT07642414 is a NA study that is actively recruiting participants, run by Hinge Health. The registered enrollment target is 140 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07642414, a NA study, is actively recruiting participants, sponsored by Hinge Health.
- RECRUITING
- Registry status
- NA
- Development phase
- 140 participants
- Enrollment target
Study Summary
This study evaluates the clinical effectiveness of the Enso for Migraine program, a comprehensive digital care program combining an FDA-cleared neuromodulation wearable device (Enso), personalized exercise therapy, and a dedicated care team, in reducing migraine frequency among adults with episodic or chronic migraine.
Primary Outcome
A migraine day is defined per ICHD-3 criteria as a calendar day with headache lasting at least 4 hours (untreated or unsuccessfully treated) with moderate-to-severe pain intensity, accompanied by nausea/vomiting or photophobia/phonophobia. Monthly Migraine Days are counted over a 28-day period using daily electronic diary data.
Interventions
- DEVICE Neuromodulation Wearable Device
- OTHER Migraine Digital Care Program
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2026-06 |
| Est. Completion | 2026-11 |
| Phase | NA |
What NCT07642414 shows while recruiting
NCT07642414 is an interventional study that assigns participants to a tested intervention. The registered 140 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 2 interventions - of which Neuromodulation Wearable Device is the first listed.
NCT07642414 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07642414 about?
NCT07642414 is a clinical study titled "A Comprehensive Digital Care Program for Migraine Management". This study evaluates the clinical effectiveness of the Enso for Migraine program, a comprehensive digital care program combining an FDA-cleared neuromodulation wearable device (Enso), personalized exercise therapy, and a dedicated care team, in reducing migraine frequency among adults with episodic ...
What is the current status of trial NCT07642414?
This trial is currently recruiting. It is a NA study. The enrollment target is 140 participants. The study started on 2026-06. Estimated completion is 2026-11.
What interventions are being tested in trial NCT07642414?
The interventions under investigation include: Neuromodulation Wearable Device (DEVICE), Migraine Digital Care Program (OTHER).
Who is sponsoring clinical trial NCT07642414?
This trial is sponsored by Hinge Health, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07642414's enrollment target sits among peer trials
140 713th of 2000 higher than 1,281 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01419561 · 140 participants · Phase 2
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
- NCT01624805 · 140 participants · Phase 2
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
- NCT02369770 · 140 participants · NA
Sensory-Motor Rehabilitation Post Stroke
- NCT02455193 · 140 participants · NA
Neuronal Effects of Exercise in Schizophrenia
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia